dacarbazine

Furthermore, treatment with AVD (adriamycin/vinblastine/dacarbazine) in combination with brentuximab vedotin (BV) was initiated to achieve a complete metabolic response. Histopathologically, SV has a high proportion of HRS cells, with high CD30-positive and low EBER-positive rates. Therefore, CD30-targeted therapies such as BV may be preferable for SV, even in localized NS-HL patients, thereby improving patient prognosis.

P2, N=60, Active, not recruiting, Henan Cancer Hospital | Recruiting --> Active, not recruiting

P2, N=92, Not yet recruiting, Suzhou BlueHorse Therapeutics Co., Ltd.

P2, N=23, Not yet recruiting, City of Hope Medical Center

Second-line treatment with tislelizumab, nab-paclitaxel, carboplatin, and anlotinib led to temporary stabilization. Salvage chemotherapy with doxorubicin, ifosfamide, and dacarbazine failed, and the patient died two months later...Patients who undergo complete resection of metastatic lesions tend to achieve better outcomes, whereas responses to systemic therapy are generally poor. Early identification of high-risk features and consideration of retroperitoneal lymph node dissection may improve prognosis in selected patients.

This is the first published case suggesting a potential role for leukotriene receptor antagonists in CYSLTR2-mutant UM. These findings support further preclinical and clinical investigation of montelukast as a repurposed therapy in this challenging disease entity.

In summary, the dacarbazine-2-AEH2P combination exhibits synergistic pharmacodynamic activity that enhances cytotoxicity through coordinated modulation of proliferative and apoptotic pathways. These findings highlight its potential as a promising strategy to improve chemotherapeutic efficacy and overcome resistance in melanoma treatment.

P2, N=54, Recruiting, National Medical Research Radiological Centre of the Ministry of Health of Russia | Trial completion date: Jan 2032 --> Jan 2029 | Trial primary completion date: Jan 2029 --> Jan 2028

P2, N=17, Active, not recruiting, Stanford University | Recruiting --> Active, not recruiting | N=25 --> 17 | Trial completion date: Dec 2025 --> May 2026 | Trial primary completion date: Dec 2025 --> May 2026

P3, N=550, Completed, Italian Sarcoma Group | Active, not recruiting --> Completed

In this study, we established chemoresistant uveal melanoma cell lines by exposing parental cells to dacarbazine, cisplatin, or gemcitabine and performed high-throughput drug screening incorporating normal human epidermal melanocytes (NHEMs) as a normal control to assess both efficacy and selectivity. Our screening identified temsirolimus and selumetinib as top candidates, with temsirolimus exhibiting strong tumor-selective cytotoxicity...Mechanistically, temsirolimus downregulated mammalian target of rapamycin (mTOR) signaling, as indicated by reduced p-mTOR, p-S6, and p-4EBP1 expression in tumor tissues. These findings demonstrate that temsirolimus selectively targets chemoresistant uveal melanoma cells, enhances chemotherapy efficacy, and suppresses tumor growth via mTOR inhibition, supporting its potential clinical application as a novel therapeutic strategy for chemoresistant uveal melanoma.